National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 45866-45867 [2017-20991]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
45866
Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices
analogues of monamine transporters to
treat substance use disorders and sleep
disorders within the scope of the
Licensed Patent Rights’’. Comments/
Objections were not received in
response to the NOITG. After
consideration, an exclusive license was
granted to EncepHeal with a Licensed
Field of Use of: ‘‘Use of analogues of
monamine transporters to treat
substance use disorders within the
scope of the Licensed Patent Rights’’.
This Notice advises the public that the
NIH intends to modify the Licensed
Field of Use originally granted to
EncepHeal. Specifically, the National
Institute on Drug Abuse is proposing to
modify the Licensed Field of Use to be
‘‘use of a lead compound to treat one or
more of the following: Substance use
disorders, cognitive deficits, sleep
disorders, attention deficit hyperactivity
disorder and depressive disorders. The
modification to the Licensed Field of
Use in the Exclusive Patent License
requires EncepHeal to select a lead
compound for each of the disorders
listed in the Field of Use and that upon
selection of a lead compound for a
disorder, the other compounds of the
technology will become available for
licensing to other companies.
The technology is directed to novel
analogues of modafinil. Modafinil
(marketed as Provisil in United States)
is approved by FDA to treat narcolepsy
and other sleep disorders. Modafinil has
been studied as a possible treatment for
cognitive dysfunction in disorders such
as attention-deficit hyperactivity
disorders (ADHD) as well as cocaine
and methamphetamine addiction.
However, it has a relatively low affinity
for dopamine transporter (DAT) and is
water-insoluble, thus requiring large
doses to achieve pharmacological
effects. Early studies indicated that
modafinil reduced cocaine intake more
effectively than placebo; however,
subsequent larger studies reported only
modest effectiveness in reducing
cocaine intake. The library of
compounds in the technology are
analogs of modafinil and are designed to
have higher affinities for DAT and
improved water solubility. The National
Institute on Drug Abuse has conducted
preliminary experiments on many of the
compounds and has identified several
compounds that have higher affinities
than modafinil for the DAT and lower
affinity than modafinil for several other
off target receptors. Preliminary studies
at the National Institute on Drug Abuse
indicate that some of the compounds
have in vivo activity in rodents to
inhibit cocaine taking behavior and are
not selectively self-administered
VerDate Sep<11>2014
19:01 Sep 29, 2017
Jkt 244001
themselves (i.e. have low abuse
liability).
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404
and incorporates by reference:
‘‘Prospective Grant of Exclusive Option
License: Potent and Selective Analogues
of: Monamine Transporters; Methods of
Making; and Uses Thereof’’ FR 80:245
(December 22, 2015), pp. 79595–79596.
The prospective modification of the
Exclusive Patent License will be royalty
bearing and may be granted unless
within fifteen (15) days from date of this
published notice, the National Institute
on Drug Abuse receives written
evidence and argument that establishes
that the grant of modification to the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR Part 404.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated
modification to Exclusive Patent
License. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 22, 2107.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–21048 Filed 9–29–17; 8:45 am]
BILLING CODE 4040–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Program Project Grant P01.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Date: October 23, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852
(Teleconference Meeting).
Contact Person: Ana Olariu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–9223, ana.olariu@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Initial
Review Group; Neurological Sciences and
Disorders A.
Date: October 23–24, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue NW., Washington, DC 20037.
Contact Person: Natalia Strunnikova,
Ph.D., Scientific Review Officer, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, (301) 402–0288, natalia.strunnikova@
nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; K99/R00 Review.
Date: October 23, 2017.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Crystal City, 2399 Jefferson
Davis Highway, Arlington, VA 22202.
Contact Person: Elizabeth A. Webber,
Ph.D., Scientific Review Officer, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, (301) 496–1917, webbere@mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Initial
Review Group; Neurological Sciences and
Disorders B.
Date: October 26–27, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Admiral Fell Inn, 888 South
Broadway, Baltimore, MD 21231.
Contact Person: Birgit Neuhuber, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–9223, neuhuber@ninds.nih.gov@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Ruth L. Kirschstein National
Research Service Award (NRSA) Institutional
Research Training Grant (T32) Program.
Date: October 30–31, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco, 700 F Street NW.,
Washington, DC 20001.
Contact Person: William Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
E:\FR\FM\02OCN1.SGM
02OCN1
Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Clinical Trials Review
Committee.
Date: October 24, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott, 5701
Marinelli Road, Rockville, MD 20852.
Contact Person: Kathy Salaita, SCD, Chief,
Scientific Review Branch, National Institute
of Arthritis and Musculoskeletal and Skin
Diseases, DHHS/National Institutes of Health,
6701 Democracy Blvd., Rm. 818, Bethesda,
MD 20892, 301–594–5033 (office), 301–402–
2406 (fax), Kathy.Salaita@nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; AMSC
Conflict Review Meeting.
Date: October 26, 2017.
Time: 11:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Arthritis and
Musculoskeletal and Skin Diseases, 6701
Democracy Boulevard, Suite 816, Bethesda,
MD 20892 (Teleconference).
Contact Person: Nakia C. Brown, Ph.D.,
Scientific Review Officer, 6701 Democracy
Boulevard, Room 816, Bethesda, MD 20892,
301–827–4905, brownnac@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: September 26, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: September 26, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–20991 Filed 9–29–17; 8:45 am]
[FR Doc. 2017–20989 Filed 9–29–17; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
sradovich on DSK3GMQ082PROD with NOTICES
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–0660, benzingw@mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; BPN Review Meeting.
Date: November 3, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Glover Park Hotel, 2505 Wisconsin
Avenue NW., Washington, DC 20007.
Contact Person: Joel Saydoff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–9223, joel.saydoff@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Initial
Review Group; Neurological Sciences and
Disorders K.
Date: November 6, 2017.
Time: 2:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529, (301)
435–6033, rajarams@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Office of the Secretary; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
19:01 Sep 29, 2017
Jkt 244001
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Frm 00073
Fmt 4703
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Muscular Dystrophy
Coordinating Committee.
Type of meeting: Open Meeting.
Date: December 5, 2017.
Time: 1:00 p.m. to 2:30 p.m. *Eastern
Time*
Agenda: The purpose of this meeting is to
bring together committee members,
representing government agencies, patient
advocacy groups, other voluntary health
organizations, and patients and families to
update one another on progress relevant to
the Action Plan for the Muscular
Dystrophies.
Place: National Institutes of Health, 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Call-In Number: 1–650–479–3208.
Public Access Code: 622 734 375.
Contact Person: Glen Nuckolls, Ph.D.,
Program Director, National Institute of
Neurological Disorders and Stroke, NIH, 6001
Executive Boulevard, Room 2203, Rockville,
MD 20892, Phone: (301) 496–5876, Email:
nuckollg@ninds.nih.gov.
Prior to the meeting, an agenda will be
posted to the MDCC Web site:
www.mdcc.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: September 26, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–20990 Filed 9–29–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Muscular Dystrophy
Coordinating Committee.
The meeting will be open to the
public and accessible by teleconference
and live WebEx. Members of the public
who wish to participate using WebEx
should contact the Contact Person listed
on this notice for the WebEx details.
Individuals who plan to participate and
need special assistance, such as
reasonable accommodations, should
PO 00000
45867
Sfmt 4703
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 82, Number 189 (Monday, October 2, 2017)]
[Notices]
[Pages 45866-45867]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20991]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Program Project Grant P01.
Date: October 23, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Teleconference Meeting).
Contact Person: Ana Olariu, Ph.D., Scientific Review Officer,
Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001
Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529,
(301) 496-9223, ana.olariu@nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Initial Review Group; Neurological Sciences and Disorders
A.
Date: October 23-24, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Melrose Hotel, 2430 Pennsylvania Avenue NW., Washington,
DC 20037.
Contact Person: Natalia Strunnikova, Ph.D., Scientific Review
Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD
20892-9529, (301) 402-0288, natalia.strunnikova@nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; K99/R00 Review.
Date: October 23, 2017.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Crystal City, 2399 Jefferson Davis Highway,
Arlington, VA 22202.
Contact Person: Elizabeth A. Webber, Ph.D., Scientific Review
Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD
20892-9529, (301) 496-1917, webbere@mail.nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Initial Review Group; Neurological Sciences and Disorders
B.
Date: October 26-27, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Admiral Fell Inn, 888 South Broadway, Baltimore, MD
21231.
Contact Person: Birgit Neuhuber, Ph.D., Scientific Review
Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD
20892-9529, (301) 496-9223, neuhuber@ninds.nih.gov@nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Ruth L. Kirschstein National
Research Service Award (NRSA) Institutional Research Training Grant
(T32) Program.
Date: October 30-31, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hotel Monaco, 700 F Street NW., Washington, DC 20001.
Contact Person: William Benzing, Ph.D., Scientific Review
Officer, Scientific Review
[[Page 45867]]
Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892-9529, (301) 496-0660,
benzingw@mail.nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; BPN Review Meeting.
Date: November 3, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Glover Park Hotel, 2505 Wisconsin Avenue NW., Washington,
DC 20007.
Contact Person: Joel Saydoff, Ph.D., Scientific Review Officer,
Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001
Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892-9529,
(301) 496-9223, joel.saydoff@nih.gov.
Name of Committee: National Institute of Neurological Disorders
and Stroke Initial Review Group; Neurological Sciences and Disorders
K.
Date: November 6, 2017.
Time: 2:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Shanta Rajaram, Ph.D., Scientific Review
Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD
20892-9529, (301) 435-6033, rajarams@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: September 26, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-20991 Filed 9-29-17; 8:45 am]
BILLING CODE 4140-01-P
